Blue Owl Capital Holdings’s Centessa Pharmaceuticals CNTA Stock Holding History

Blue Owl Capital Holdings’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-139,450	Closed	-$3.49M	–	77
2025 Q4	$3.49M	Sell	139,450 -30,000	-18%	-$760K	1.08%	27
2025 Q3	$4.11M	Sell	169,450 -161,150	-49%	-$2.86M	1.28%	24
2025 Q2	$4.34M	Buy	330,600 +15,600	+5%	+$198K	1.4%	21
2025 Q1	$4.53M	Buy	315,000 +95,000	+43%	+$1.55M	1.46%	17
2024 Q4	$3.69M	Sell	220,000 -35,000	-14%	-$580K	0.85%	26
2024 Q3	$4.08M	Buy	+255,000	New	+$3.12M	0.79%	29

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Blue Owl Capital Holdings's CNTA Position: Q1 2026 in Review

Blue Owl Capital Holdings sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 139,450 shares — an estimated $3.49M sold.

Blue Owl Capital Holdings first reported a position in CNTA in Q3 2024 and held it in 6 quarters. The position peaked at $4.53M in Q1 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Blue Owl Capital Holdings reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Blue Owl Capital Holdings sold 139,450 Centessa Pharmaceuticals shares in Q1 2026, an estimated $3.49M.
Blue Owl Capital Holdings first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 6 quarters.
Blue Owl Capital Holdings's Centessa Pharmaceuticals position peaked at $4.53M in Q1 2025.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.